TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00378508
Drug: Placebo Arm
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02064504
Drug: GSK961081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white to off white powder
Study: NCT02597699
Drug: Remifentanil + Lidocaïne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02597699
Drug: Sufentanil + Lidocaïne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03836885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
Study: NCT02584257
Drug: placebo ProAir HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00713791
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period 1: 10mg oral solution
Study: NCT00713791
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study: NCT00713791
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study: NCT00713791
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study: NCT04065971
Drug: 2LHERP®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04065971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT03560011
Drug: immunoglobulin IV
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
Study: NCT00849511
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
Study: NCT02865785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
Study: NCT00868894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular application
Study: NCT01697826
Drug: ClinSupV3ER- Extended release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
Study: NCT00878800
Drug: PXD101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in combination with doxorubicin (BelDox)
Study: NCT00878800
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered in combination with PXD101 (BelDox)
Study: NCT01172223
Drug: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m\^2 i.v. day 1 q3 weeks
Study: NCT02610543
Drug: UCB5857
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
Study: NCT02610543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
Study: NCT00613691
Drug: SPI-1620
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
Study: NCT02463929
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT00254800
Drug: ethinyl estradiol and levonorgestrel; exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
Study: NCT03648437
Drug: Paracetamol 10Mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT03648437
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard therapy
Study: NCT03648437
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy
Study: NCT03396315
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
Study: NCT01035164
Drug: F-18 FEDAA1106 (BAY85-8101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
Study: NCT02452632
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02452632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02380625
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
Study: NCT01270464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
Study: NCT03526536
Drug: IV Novolin R human insulin
Normalized name: insulin, regular, human Injectable Solution [Novolin R]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
Study: NCT02372812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751049
Drug: PhXA41
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study: NCT00004875
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00441376
Drug: ThermoDox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
Study: NCT03214380
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03611777
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT01872598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872598
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Study: NCT03788434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
Study: NCT02490787
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT04582929
Drug: Neuronox ® Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuronox ® 50 or 100 unit intramuscular injection
Study: NCT03473639
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
Study: NCT02837939
Drug: Human derived Transfer factor
Normalized name: brain-derived neurotrophic factor, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month
Study: NCT00270153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg enalapril-matching placebo daily for 6 months
Study: NCT01448109
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
Study: NCT00452673
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
Study: NCT02218099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03650543
Drug: amoxicillin clarithromycin omeprazole 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
Study: NCT03650543
Drug: amoxicillin clarithromycin omeprazole 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
Study: NCT00790244
Drug: doxorubicin , ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
Study: NCT00790244
Drug: doxorubicin, ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Study: NCT00790244
Drug: doxorubicin, ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Study: NCT01579084
Drug: AGN-199201 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.
Study: NCT01579084
Drug: AGN-199201 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Study: NCT06685341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02176863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: NCT02424630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
Study: NCT03607071
Drug: Prednisolone and taper
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
Study: NCT01949844
Drug: Optimark®
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
Study: NCT03483649
Drug: US-Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study: NCT03483649
Drug: EU-Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study: NCT03483649
Drug: CN-Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study: NCT03784105
Drug: Codeine Phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mL of codeine phosphate 10mg/5mL
Study: NCT03784105
Drug: Siripus simplex
Normalized name: Ruellia simplex whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar syrup
Study: NCT01818869
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses inhaled IMP via a nebulizer
Study: NCT01818869
Drug: Placebo to match AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses inhaled matching placebo via a nebulizer
Study: NCT01536366
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BIA 9-1067 (single-dose)
Study: NCT00446368
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
Study: NCT00436267
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01902004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
Study: NCT01572805
Drug: melatonin 3mg
Normalized name: MELATONIN 3MG TAB
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To receive sublingual 3 mg melatonin before spinal of anesthesia .
Study: NCT01572805
Drug: melatonin 6mg
Normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To receive sublingual 6 mg melatonin before spinal of anesthesia .
Study: NCT01572805
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To receive sublingual placebo tablet before spinal of anesthesia .
Study: NCT01324076
Drug: doxorubicin-eluting beads
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00532766
Drug: Jusline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01600365
Drug: Ophthalmic gel (placebo)
Normalized name: Ophthalmic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
Study: NCT00900900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-time dose oral dose
Study: NCT02401490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00442182
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03694964
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
Study: NCT04290208
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen
Study: NCT04290208
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen liquid syrup
Study: NCT04290208
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored, non-medicated (placebo) liquid syrup
Study: NCT00390845
Drug: SB681323
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 milligrams (mg)/day
Study: NCT00390845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04290208
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV salt solution (non-medicated)
Study: NCT02404688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
Study: NCT02404688
Drug: Active Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Study: NCT02404688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: no alcohol, administered for a total of 80 minutes.
Study: NCT01404156
Drug: (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)
Study: NCT04446299
Drug: Bowel Prep
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally ingested liquid bowel preparation
Study: NCT04436016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol will be encapsulated for adequate blinding.
Study: NCT00096616
Drug: Combivent® CFC MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217410
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01022125
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01895881
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01895881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01940887
Drug: E10030
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02754687
Drug: 11βmethyl nortestosterone dodecylcarbonate
Normalized name: 17-Ethynyl-18-methyl-19-nortestosterone
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
Study: NCT00312832
Drug: switching; dose reduction
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01906307
Drug: LJPC-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
Study: NCT05269173
Drug: Flos gossypii flavonoids tablet
Normalized name: Aller-Flo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Study: NCT01472016
Drug: ABT-700
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
Study: NCT01472016
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
Study: NCT02051790
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
Study: NCT01391520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study: NCT00236301
Drug: CLIMASTON (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLIMASTON(drug)
Study: NCT00236301
Drug: 17 Beta-estradiol (2mg/day)and (1mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 Beta-estradiol (2mg/day)and (1mg/day)
Study: NCT00236301
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00002488
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes